MRKC:F:F-MERCK KGAA NAM.SP.ADR (EUR)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 29.6

Change

-0.20 (-0.67)%

Market Cap

USD 67.42B

Volume

276.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-26 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
MRK:F Merck & Company Inc

-0.50 (-0.32%)

USD 66.78B
ZOE:F Zoetis Inc

+2.00 (+1.31%)

USD 64.18B
TKD:F Takeda Pharmaceutical Company ..

-0.21 (-0.87%)

USD 39.41B
TKDA:F Takeda Pharmaceutical Company ..

-0.30 (-2.46%)

USD 38.72B
H6D0:F Haleon PLC

-0.04 (-1.12%)

USD 35.13B
H6D:F Haleon PLC

-0.10 (-1.36%)

USD 35.12B
TEV:F Teva Pharmaceutical Industries..

-0.10 (-0.67%)

USD 14.69B
SH0:F Shionogi & Co. Ltd

+0.40 (+0.92%)

USD 12.76B
NB3:F Neurocrine Biosciences Inc

-0.80 (-0.61%)

USD 12.70B
RDDA:F Dr. Reddy's Laboratories Limit..

-1.00 (-1.52%)

USD 11.53B

ETFs Containing MRKC:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.96% 57% F 60% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.96% 52% F 55% F
Trailing 12 Months  
Capital Gain -6.92% 58% F 43% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -6.92% 52% F 39% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -5.82% 49% F 28% F
Dividend Return -5.82% 47% F 26% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 7.94% 93% A 86% B+
Risk Adjusted Return -73.34% 13% F 4% F
Market Capitalization 67.42B 100% F 97% N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.